The Gulf journal of oncology最新文献

{"title":"Quality of Life (QoL) using EORTC QoL-C30 and BN20 among Patients who Underwent Brain Tumor Resection in a Tertiary Care Center in Saudi Arabia.","authors":"Rana H Moshref, Leena H Moshref, Fatemah A Alhalawani, Ahmed AlLawati, Masaheer A Aljehani, Noor M Shibriq, Wafa A Saber, Ahlam B Khojah, Rawan M Alsayed, Razan Daghistani, Khalid M Bajunaid, Mohammed A Alyousef, Abdulrahman J Sabbagh, Saleh S Baeesa","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Quality of life (QoL) encompasses the awareness of individuals' well-being in various aspects of their lives, including physical, personal, mental, and social domains. It is imperative to address QoL concerns in patients with brain tumors. The objective of this study is to assess the QoL among brain tumor patients treated a tertiary hospital in Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective study conducted at a single academic institution in 2017 analyzed data from adult patients diagnosed with brain tumors who underwent craniotomy and resection procedures over a 10-year period (2007-2017). The assessment of QoL was conducted employing a translated Arabic questionnaire derived from the European Organization for Research and Treatment of Cancer (EORTC) standardized model (QLQ-C30). This model evaluates various domains, including global health, physical function, role functioning, emotional functioning, cognitive functioning, social functioning, and symptoms domain. Furthermore, the brain cancer model (BN20) was utilized to assess symptoms and evaluate all aspects of well-being.</p><p><strong>Results: </strong>In this study, a total of 76 patients were included, with a median age of 46 years. No gender bias was observed. Meningioma was the most prevalent brain tumor in our study, comprising 40% of the cases, followed by glioma and other types. It is noteworthy that more than half (65%) of the brain tumor patients had a World Health Organization (WHO) grade I brain tumor, while 15% had grade II, and 20% had grades III or IV. Supratentorial was the most common location for brain tumors. In all types of brain tumors, particularly in patients who underwent resection of meningioma and glioma, the QoL scales and measurements of daily functioning consistently exhibited low scores. Better QoL scores were correlated with male gender, the location of the brain tumor, and the WHO tumor grade. Conversely, perioperative headache, drowsiness, neurological deficits, and low socioeconomic status were associated with poor QoL.</p><p><strong>Conclusion: </strong>Our study is the first study reported in Saudi Arabia to evaluate the quality of life of patients undergoing surgical procedures for brain tumors. We demonstrated that the QoL experienced by brain tumor patients consistently appeared to be poor, irrespective of the specific type of tumor. We underscore the paramount significance of evaluating the QoL of brain tumors within the Gulf and Middle East regions. To comprehensively evaluate the QoL of brain tumor patients globally, a substantial sample size and longitudinal or prospective studies are indispensable.</p>","PeriodicalId":523894,"journal":{"name":"The Gulf journal of oncology","volume":"1 49","pages":"53-64"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148220648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De novo mutation of the RET proto-oncogene revealing multiple endocrine neoplasia type 2A: a sporadic case from Western Algeria.","authors":"Amina Chami, Pauline Romanet, Fatima Mohammedi, Nadia Benabadji, Narimane Habour, Dalia Derkaoui, Tewfik Sahraoui","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Multiple endocrine neoplasia type 2A (MEN2A) is a rare autosomal dominant disorder associated with RET proto-oncogene mutations. Early diagnosis is absolutely critical for managing and preventing aggressive forms of medullary thyroid carcinoma (MTC) and associated tumours. Our aims are to confirm the clinical diagnosis and to detect, in relatives, those who bear the familial mutation in order to benefit from medical management before the first symptoms appear.</p><p><strong>Case presentation: </strong>We report a sporadic case of MEN2A in a 34-year-old woman from western Algeria. She presented with bilateral medullary thyroid carcinoma and a left pheochromocytoma.</p><p><strong>Results: </strong>Genetic analysis by nextgeneration sequencing revealed a de novo heterozygous c.1901G>C (p.Cys634Ser) mutation in exon 11 of the RET gene. This is a well-known pathogenic variant associated with MEN2A.</p><p><strong>Discussion: </strong>This case proves that RET genetic testing is vital in all cases of MTC, even in those without a family history, as de novo mutations can occur. The absence of this variant in the patient's first-degree relatives confirms the de novo origin, possibly linked to advanced paternal age.</p><p><strong>Conclusion: </strong>Systematic genetic screening and counselling are essential for the early diagnosis and appropriate management of MEN2A, particularly in sporadic cases. Broader implementation of molecular testing and genetic counselling in Algeria is recommended to improve patient outcomes and prevent transmission to future generations.</p>","PeriodicalId":523894,"journal":{"name":"The Gulf journal of oncology","volume":"1 49","pages":"35-39"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes of Penile Cancer Patients undergoing Primary Surgery: Experience from a Tertiary Cancer Care Centre in South India.","authors":"Ricky Koshy Benjamin, Sivaranjith J, Madhu Muralee, Aswin Kumar, Jagathnath Krishna K M","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Historically, the management of inguinal nodes in node-negative carcinoma penis has been a topic of debate. The chance of harboring micrometastasis in inguinal nodes in clinically node-negative patients is up to 25%. Dynamic sentinel node biopsy and elective inguinal lymph node dissection have flaws of false negativity and morbidity.</p><p><strong>Methodology: </strong>This is a retrospective study on patients with carcinoma penis treated between January 2010 and August 2019 who underwent upfront surgery for the disease. Patients who were clinically and radiologically node-negative underwent surgery for the primary disease only, and were kept under follow-up for nodal recurrence, while those with suspicious nodes clinically or radiologically underwent inguinal node dissection.</p><p><strong>Results: </strong>77 patients were included in the study. Of the 50 patients who were clinically and radiologically nodenegative and did not undergo nodal dissection or invasive nodal staging, 21 had recurrence. Of the 27 patients who had node dissection, 16 were pathologically negative. Nine out of 16 patients with pathologically node-negative and seven out of 11 patients with pathologically node positive disease had recurrence. The median Overall survival (OS) and the median Recurrence free survival (RFS) were 77 and 75 months, respectively. The median OS in nodal observation and pathologically nodenegative group were 92 and 79 months, respectively (p- 0.266). The median RFS in nodal observation and pathologically node-negative group were 90 and 74 months, respectively (p- 0.182).</p><p><strong>Conclusions: </strong>Our series shows that in properly evaluated clinically and radiologically node negative patients kept under observation, OS and RFS are comparable with pathologically node-negative patients, opening a window for nodal observation, thus avoiding morbidities of ilioinguinal block dissection or invasive nodal staging.</p>","PeriodicalId":523894,"journal":{"name":"The Gulf journal of oncology","volume":"1 49","pages":"7-15"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Paclitaxel Plus Ramucirumab as Second-Line Therapy in Advanced Gastric Cancer: A Retro-Prospective Single-Centre Study.","authors":"Varun Goel, Arpit Jain, Nivedita Patnaik, Dharmistha Basu, Shaifali Goel, Akanksha Jaju, Vineet Talwar, Shivendra Singh","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Advanced gastric cancer (AGC) has limited treatment options beyond first-line therapy. The combination of paclitaxel and ramucirumab is an approved second-line regimen. This study evaluates the real-world efficacy and safety of this combination in Indian patients.</p><p><strong>Aim: </strong>To assess the effectiveness and tolerability of paclitaxel plus ramucirumab in advanced gastric/gastroesophageal junction adenocarcinoma in a real-world setting.</p><p><strong>Materials and methods: </strong>This retro-prospective study included 85 patients with AGC treated between January 2020 and December 2024 at a tertiary cancer centre in North India. Patients received paclitaxel 80 mg/m² on days 1, 8, and 15, and ramucirumab 8 mg/kg on days 1 and 15 of a 28-day cycle. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.</p><p><strong>Results: </strong>The median age was 58 years; 71% were male. ECOG PS 0-1 was present in 70%. Prior gastrectomy was reported in 36%. Median PFS was 5.1 months, and OS was 9.3 months. ORR was 27%, and DCR was 66%. Common grade 3/4 adverse events included neutropenia (19%), neuropathy (13%), and hypertension (9%).</p><p><strong>Conclusion: </strong>Paclitaxel plus ramucirumab is effective and well-tolerated as second-line treatment in Indian AGC patients. Outcomes mirror global data and support its continued use in resource-limited settings.</p>","PeriodicalId":523894,"journal":{"name":"The Gulf journal of oncology","volume":"1 49","pages":"75-79"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental Radiation Exposure to the Internal Mammary Lymph Nodes in Breast Cancer Patients Undergoing Intensity-Modulated Radiation Therapy: A Retrospective Analysis.","authors":"Vishwadeep Mishra, Shashank Shekhar, Sudeep Bisht, Rachita Chatterjee, Laxman Pandey, Archana Pandey","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) remains the most common malignancy among Indian women, with Stage III being the most frequent at diagnosis. While radiation therapy (RT) plays a pivotal role in the adjuvant treatment of breast cancer, the inclusion of internal mammary lymph nodes (IMLNs) in the radiation field remains controversial due to potential cardiopulmonary toxicity. However, the extent of incidental radiation to the IMLNs, especially with forward planning intensity-modulated radiation therapy (IMRT), remains under-explored.</p><p><strong>Objective: </strong>This study aimed to evaluate the incidental radiation dose received by the IMLNs in patients with leftsided breast cancer treated with forward planning IMRT.</p><p><strong>Materials and methods: </strong>A total of 36 left-sided breast cancer patients, aged 35-60 years, who underwent modified radical mastectomy followed by adjuvant RT using IMRT, were retrospectively analyzed. CT-based planning and contouring were performed according to RTOG guidelines, with IMLNs contoured retrospectively using Jetwa et al.'s method. Dosimetric parameters for the planning target volume (PTV) and IMLNs were extracted and analyzed using dose-volume histograms. Statistical comparisons were made using the dependent Student's t-test.</p><p><strong>Results: </strong>The PTV received effective radiation coverage with a mean D95 of 38.47 Gy and a mean Dmean of 40.10 Gy. The IMLNs, although not directly targeted, received significant incidental radiation, with a mean D95 of 8.49 Gy, D50 of 21.59 Gy, and Dmean of 21.40 Gy. The maximum dose to the IMLNs (Dmax) reached 38.14 Gy. Comparative analysis revealed statistically significant differences in both Dmax and Dmean between PTV and IMLNs (p = 0.004 and p < 0.001, respectively).</p><p><strong>Conclusion: </strong>Forward planning IMRT provides substantial incidental radiation exposure to the IMLNs, which may have therapeutic implications in reducing recurrence risk. However, this exposure also necessitates careful consideration of potential long-term toxicities to adjacent organs. Further prospective studies are warranted to evaluate the clinical outcomes associated with incidental IMLN irradiation.</p>","PeriodicalId":523894,"journal":{"name":"The Gulf journal of oncology","volume":"1 49","pages":"16-21"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}